EU's CHMP recommends label extension for Genzyme's CholestaGel
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended a label extension for Genzyme's oral bile acid sequestrant, CholestaGel (colesevelam hydrochloride) to include its use in combination with Merck & Co's cholesterol absorption inhibitor Zetia (ezetimibe), with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia.